They make up 0.4 to 0.6 percent of all intracranial neoplasms in children and are the third most prevalent congenital brain tumors after teratomas and gliomas.

[8] Signs of the tumor resulting from increased intracranial pressure are present in 91% of patients, with vomiting, homonymous visual field defects and headache being the most common symptoms.

Other symptoms are ear ringing and nausea, loss of balance and mobility, worsening eyesight, memory issues, brain fog, and mood swings.

[11] Up to 20% of choroid plexus papilloma patients may test positive for glial fibrillary acidic protein (GFAP).

[15] An isodense or slightly hyperdense lesion inside the ventricles, as well as the resulting ventriculomegaly, are visible on computer tomography (CT).

[16] The intraventricular lobulated masses are well-defined and resemble fronds; they are hypointense on T1WI and hyperintense on T2WI on magnetic resonance imaging (MRI).

Such a policy has the drawback that patients may experience focused deficiencies as a result of seizures, subarachnoid hemorrhage, or mass impact.

Because of recent improvements in imaging, surgical techniques, and intensive care quality, the chance of a cure has reached nearly 100% .

[4] Significant (12 percent) perioperative mortality occurs in the juvenile population, with catastrophic blood loss accounting for the majority of cases.

[23] To decrease blood flow and increase tumor resectability, percutaneous stereotactic intratumoral embolization with a sclerosing agent has also been tried.

[25] Irradiation followed by subtotal resection may be used to treat a developing residual choroid plexus papilloma, making it more likely to success.

[26] Bevacizumab is playing a bigger part in disseminated choroid plexus papilloma, according to recent research.

[31] Children who have had their intracranial pressure elevated for a long time may come with symptoms such papilledema, optic atrophy, and vision loss that may not improve after surgery.